These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28322598)

  • 1. Screening and Functional Profiling of Small-Molecule HIV-1 Entry and Fusion Inhibitors.
    Giroud C; Du Y; Marin M; Min Q; Jui NT; Fu H; Melikyan GB
    Assay Drug Dev Technol; 2017; 15(2):53-63. PubMed ID: 28322598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors.
    Marin M; Du Y; Giroud C; Kim JH; Qui M; Fu H; Melikyan GB
    Assay Drug Dev Technol; 2015 Apr; 13(3):155-66. PubMed ID: 25871547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors.
    Rossi F; Querido B; Nimmagadda M; Cocklin S; Navas-Martín S; Martín-García J
    Retrovirology; 2008 Oct; 5():89. PubMed ID: 18837996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high throughput Cre-lox activated viral membrane fusion assay identifies pharmacological inhibitors of HIV entry.
    Esposito AM; Cheung P; Swartz TH; Li H; Tsibane T; Durham ND; Basler CF; Felsenfeld DP; Chen BK
    Virology; 2016 Mar; 490():6-16. PubMed ID: 26803470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
    Platt EJ; Durnin JP; Kabat D
    J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay.
    Yang E; Gardner MR; Zhou AS; Farzan M; Arvin AM; Oliver SL
    PLoS One; 2018; 13(10):e0206365. PubMed ID: 30359435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV cell fusion assay: phenotypic screening tool for the identification of HIV entry inhibitors via CXCR4.
    Smith EB; Ogert RA; Pechter D; Villafania A; Abbondanzo SJ; Lin K; Rivera-Gines A; Rebsch-Mastykarz C; Monsma FJ
    J Biomol Screen; 2014 Jan; 19(1):108-18. PubMed ID: 23989454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
    Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
    PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoside analogs of beta-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry.
    Garg H; Francella N; Tony KA; Augustine LA; Barchi JJ; Fantini J; Puri A; Mootoo DR; Blumenthal R
    Antiviral Res; 2008 Oct; 80(1):54-61. PubMed ID: 18538869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a future for antiviral fusion inhibitors?
    Berkhout B; Eggink D; Sanders RW
    Curr Opin Virol; 2012 Feb; 2(1):50-9. PubMed ID: 22440966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions.
    Giroud C; Marin M; Hammonds J; Spearman P; Melikyan GB
    J Virol; 2015 Sep; 89(18):9368-82. PubMed ID: 26136569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.
    Garcia-Perez J; Staropoli I; Azoulay S; Heinrich JT; Cascajero A; Colin P; Lortat-Jacob H; Arenzana-Seisdedos F; Alcami J; Kellenberger E; Lagane B
    Retrovirology; 2015 Jun; 12():50. PubMed ID: 26081316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
    Ray N; Harrison JE; Blackburn LA; Martin JN; Deeks SG; Doms RW
    J Virol; 2007 Apr; 81(7):3240-50. PubMed ID: 17251281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Originality of entry inhibitors].
    Izopet J
    Med Mal Infect; 2009 Oct; 39(10 Suppl 1):H1-4. PubMed ID: 19837343
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
    Panos G; Watson DC
    Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
    Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
    Verrier F; Borman AM; Brand D; Girard M
    AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
    Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
    Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.
    Ketas TJ; Schader SM; Zurita J; Teo E; Polonis V; Lu M; Klasse PJ; Moore JP
    Virology; 2007 Aug; 364(2):431-40. PubMed ID: 17428517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.